- Malignant pleural mesothelioma in patients with unresectable disease or who are not candidates for curative surgery:
- IV 500mg/m2/dose *1 on day 1 of 21-day cycle
- Used with cisplatin
- Non-squamous non-small cell lung carcinoma in locally advanced/metastatic disease:
- Initial treatment: IV 500mg/m2/dose *1 on day 1 of 21-day cycle (6 cycles)
- Maintenance: IV 500mg/m2/dose *1 on day 1 of 21-day cycle
- Initiated after 4 cycles of platinum-based first-line treatment
- Injection:
- 100mg
- 500mg
- Initiate vitamin supplementation with IM vitamin B12 and PO folic acid 1 week before 1st dose and continue during treatment and for 3 weeks after last dose
Folate antimetabolite; anticancer
It disrupts folate-dependent metabolic processes necessary for cell replication
- Fatigue
- Nausea
- Anemia
- Anorexia
- Vomiting
- Stomatitis
- Pharyngitis
- Neutropenia
- Rash
- Increased ALT/AST
- Thrombocytopenia
- Diarrhea
- Pruritus
- Sensory neuropathy
- Edema
- Alopecia
- Constipation
- Infection
- Febrile neutropenia
- Fever
- Conjunctivitis
- Increased lacrimation
- Hypersensitivity to components
- Pregnancy
- CrCl <45
- ANC <1500
- Plt <100,000
- Breastfeeding during treatment and for 1 week after discontinuation
- Cidofovir
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Contraindicated |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Pemita | 100mg | Injection | 1’s | Atlanta Biologicals | Synermed Pharma |
| Pemita | 500mg | Injection | 1’s | Atlanta Biologicals | Synermed Pharma |